Global Antisense Oligonucleotides (ASO) Therapy Market Growth (Status and Outlook) 2024-2030

Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases.

The global Antisense Oligonucleotides (ASO) Therapy market size is projected to grow from US$ 3938 million in 2024 to US$ 10620 million in 2030; it is expected to grow at a CAGR of 18.0% from 2024 to 2030.

ReportPrime's newest research report, the “Antisense Oligonucleotides (ASO) Therapy Industry Forecast” looks at past sales and reviews total world Antisense Oligonucleotides (ASO) Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Antisense Oligonucleotides (ASO) Therapy sales for 2023 through 2029.

• With Antisense Oligonucleotides (ASO) Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense Oligonucleotides (ASO) Therapy industry.
• This Insight Report provides a comprehensive analysis of the global Antisense Oligonucleotides (ASO) Therapy landscape and highlights key trends related to:
• Product segmentation
• Company formation
• Revenue and market share
• Latest development and M&A activity

This report also analyses the strategies of leading global companies with a focus on Antisense Oligonucleotides (ASO) Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antisense Oligonucleotides (ASO) Therapy market.

This Insight Report evaluates key market trends, drivers, and affecting factors shaping the global outlook for Antisense Oligonucleotides (ASO) Therapy and breaks down the forecast by:

• Type
• Application
• Geography and market size

to highlight emerging pockets of opportunity.

1. Segmentation by Type:
• Intrathecal Injection
• Intravenous Injections
• Other

1. Segmentation by Application:
• Neuromuscular Diseases
• hATTR
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, and market penetration:

• Ionis Pharmaceuticals
• Biogen
• Sobi
• Nippon Shinyaku
• Jazz Pharmaceuticals